[10]Lee ATM, Ou SI. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generati...
2. Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:2251-8...
[4] Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer[J]. J Clin Oncol. 2018;36(22):2251-2258. [5] Rothschild SI. Ceritinib-a second-generation ALK inhi...
2. Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018, 36(22):2251-2258. 3. Soria JC, Tan DSW, Chiari R, et al. First-line ...
在约50-60%对第二代ALK-TKI耐药的患者中,ALK基因激酶结构域出现的继发突变(Secondary Mutation)是导致耐药的原因,涉及的机制包括直接阻碍ALK-TKI与位点结合,导致蛋白激酶构象改变和/或影响ATP结合等。 与第一代/第二代EGFR-TKI的耐药继发突变大多为T790M突变不同,ALK继发突变的类型很多,目前主要的已知突变有L1196...
[7] Pelish H E, Tangpeerachaikul A, Kohl N E, et al. Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation[J]. Cancer Research, 2021, 81(13 Supplement): 1468. ...
9、Solomon B J, Kim D W, Wu Y L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer[J]. Journal of Clinical Oncology, 2018, 36(22): 2251-2258. ...
We carried out a meta-analysis of 709 neuroblastoma tumors to determine their frequency and mutation spectrum in relation to genomic and clinical parameters, and studied the prognostic significance of ALK copy number and expression. EXPERIMENTAL DESIGN: The frequency and type of ALK mutations, copy ...
9、Solomon B J, Kim D W, Wu Y L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer[J]. Journal of Clinical Oncology, 2018, 36(22): 2251-2258. ...
[3]NCCN Guidelines Version 5.2022 Non-Small Cell Lung Cancer.[4]Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.[5]Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer.[...